Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
Artelo Biosciences, Inc. (ARTL)
US:NASDAQ Investor Relations:
artelobio.com/investors
Company Research
Source: GlobeNewswire
SOLANA BEACH, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the United Kingdom’s Home Office has classified the Company’s lead clinical cannabinoid, ART27.13, as “non-controlled” and, therefore, is no longer considered a Schedule 1 controlled substance, which would impose limitations on its production, possession, and supply. The Home Office is the lead government department tasked with major economic, security and safety policies, including drug policy. “Collaborating diligently with the Home Office, Artelo was successful in working with governmental regulators to determine that the chemical composition of ART27.13 should not be covered by the Misuse of Drugs Act and, by virtue of the ongoing clinical trials, was also exempted from the Psychoactive Substances Act in the U.K.,” stated Andrew Yates, Ph.D., Chief Scientific Officer of Artelo Biosciences. “As a result, Artelo will be able to treat ART27.13 as a normal, non-scheduled I
Show less
Read more
Impact Snapshot
Event Time:
ARTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTL alerts
High impacting Artelo Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ARTL
News
- Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateGlobeNewswire
- Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation ChallengeGlobeNewswire
- Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th Accesswire
ARTL
Sec Filings
- 3/25/24 - Form 10-K
- 3/4/24 - Form 8-K
- 3/1/24 - Form 4
- ARTL's page on the SEC website